SMG9 Inhibitors
Chemical inhibitors of SMG9 can influence the protein's function through various biochemical pathways. PF-8380, for example, targets autotaxin, disrupting the lysophosphatidic acid (LPA) signaling pathway. As LPA signaling can modulate nonsense-mediated mRNA decay (NMD), where SMG9 operates, PF-8380 indirectly affects SMG9's activity. LY294002, a PI3K inhibitor, impacts multiple cellular processes, potentially including those regulated by SMG9. By dampening PI3K signaling, LY294002 can lead to a reduction in SMG9's functional involvement. Rapamycin, an mTOR inhibitor, can decrease mRNA translation processes, thus affecting the functional role of SMG9 in mRNA surveillance. Similarly, Spautin-1 can alter mRNA decay mechanisms regulated by cellular stress responses, including autophagy, thus influencing SMG9 activity.
Continuing with the theme of cellular process disruption, Genistein's inhibition of tyrosine kinase activity can decrease SMG9 function as it may regulate signaling pathways where SMG9 is involved. GW4869, which inhibits neutral sphingomyelinase, can alter cell signaling and membrane dynamics, thereby affecting SMG9's pathway. U0126 and SB203580, inhibitors of MEK1/2 and p38 MAPK respectively, can lead to decreases in their corresponding signaling pathways, which are implicated in mRNA stability and decay processes that involve SMG9. Bafilomycin A1's inhibition of V-ATPase disrupts endosomal-lysosomal acidification, a vital process for cellular function, which may impact SMG9 activity. MG132 targets the proteasome system, affecting the turnover of proteins linked to mRNA decay and indirectly impacting SMG9's role in mRNA surveillance. Lastly, Cycloheximide and Actinomycin D, by inhibiting eukaryotic protein biosynthesis and DNA-dependent RNA synthesis respectively, can alter the protein and mRNA landscape, thus affecting the functional context in which SMG9 operates.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K signaling can affect multiple cellular processes including those that may involve SMG9 function. By inhibiting PI3K, LY294002 can lead to a decrease in cellular activities where SMG9 is potentially involved, thereby inhibiting SMG9's functional role. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a central regulator of cell growth and proliferation. SMG9 is known to be involved in mRNA surveillance. The inhibition of mTOR by Rapamycin can lead to a decrease in mRNA translation processes where SMG9 may play a role, thereby functionally inhibiting SMG9. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 is a specific inhibitor of autophagy. SMG9 is linked to mRNA decay, a process that can be regulated by cellular stress responses including autophagy. Inhibition of autophagy by Spautin-1 can lead to altered mRNA decay mechanisms, potentially inhibiting SMG9 function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. Tyrosine kinase activity can regulate several signaling pathways that could intersect with SMG9's functional roles. The inhibition of these kinases by Genistein can lead to decreased function of SMG9 as related pathways are inhibited. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), which impacts sphingolipid metabolism. Sphingolipids are involved in cell signaling and membrane dynamics, which may interact with the pathway of SMG9. Inhibiting nSMase with GW4869 can lead to functional inhibition of SMG9 by altering cell membrane-associated events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. The MAPK pathway can regulate mRNA stability and processing, where SMG9 is active. Inhibiting MEK with U0126 can lead to a decrease in MAPK pathway signaling, potentially inhibiting SMG9 function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which is involved in stress responses and mRNA decay. Given SMG9's role in mRNA surveillance, inhibition of p38 MAPK by SB203580 can result in functional inhibition of SMG9 by reducing its ability to regulate mRNA decay. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is an inhibitor of vacuolar-type H+-ATPase (V-ATPase). By inhibiting V-ATPase, Bafilomycin A1 disrupts endosomal-lysosomal acidification, which is crucial for various cellular processes, potentially including those regulated by SMG9. This disruption can lead to the functional inhibition of SMG9. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor. While SMG9 is involved in mRNA surveillance, the ubiquitin-proteasome system plays a role in the degradation of proteins linked to mRNA decay. Inhibition of the proteasome by MG132 can indirectly inhibit the function of SMG9 by affecting protein turnover related to mRNA surveillance. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide is an inhibitor of eukaryotic protein biosynthesis. Although it primarily impacts translation, its effects on protein synthesis can indirectly inhibit SMG9's function in mRNA surveillance by altering the protein context in which SMG9 operates. | ||||||